GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...
GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.
While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...
Medpage Today on MSN9d
Use of GLP-1 Drugs for Obesity Linked to Lower Risk of GlaucomaUse of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
For instance, the review showed that GLP-1 drugs may have promising outcomes for people with dementia or other neurological disorders. “There is also evidence for mechanisms involving a ...
Why would this be the case? The first reason is because the mechanism of action [MOA] of using a GLP-1 Receptor Agonist to help obesity patients lose weight is already established. Not only that ...
Stopping GLP-1 receptor agonists 14 days prior to total hip or knee arthroplasty may reduce several key risk factors ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback